A number of prevalent metabolic disorders such as obesity, atherosclerosis and type 2 diabetes mellitus are associated with a shift in this balance, so PPARα and PPARγ in particular, are of interest pharmacologically (25). This evidence concerns the gene PPARA and Other metabolic disease.